Sight Sciences (NASDAQ:SGHT – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.
Valuation and Earnings
This table compares Sight Sciences and ENDRA Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sight Sciences | $77.36 million | 3.55 | -$38.43 million | ($0.71) | -7.11 |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.15) | -0.68 |
Volatility & Risk
Sight Sciences has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Sight Sciences and ENDRA Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
Sight Sciences presently has a consensus price target of $8.25, suggesting a potential upside of 63.37%. ENDRA Life Sciences has a consensus price target of $25.00, suggesting a potential upside of 351.26%. Given ENDRA Life Sciences’ higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Sight Sciences.
Profitability
This table compares Sight Sciences and ENDRA Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
| ENDRA Life Sciences | N/A | -433.64% | -204.58% |
Insider & Institutional Ownership
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Sight Sciences beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
